Pharmaceutical

Hanmi and MEDiC ink cancer biomarker collaboration deal

The agreement will see MEDiC’s MCAT platform identify biomarkers to support the development of Hanmi’s clinical assets.

Oct 16, 2024 - 04:00
Hanmi and MEDiC ink cancer biomarker collaboration deal
The agreement will see MEDiC’s MCAT platform identify biomarkers to support the development of Hanmi’s clinical assets.
Read the original article

Tags:

Previous Article

Cell and gene therapy approvals drive paradigm change in manufacturing

Next Article

Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: U.S. Anesthesia Partners, Welsh Carson face class action over monopoly allegations

STAT+: U.S. Anesthesia Partners, Welsh Carson face clas...

Nov 23, 2023

Omalizumab biosimilar by Teva Pharmaceutical Industries...

Jun 18, 2024

Accord gears up to commercialise Hipra’s Covid-19 vaccine in the UK

Accord gears up to commercialise Hipra’s Covid-19 vacci...

Aug 4, 2023